- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A new regulator of 'stemness' to create dendritic cell factories for immunotherapy
- Advanced imaging interrogation of pathogen induced NETosis
- Cancer driver deserts
- Cryo-electron microscopy of Wnt signalling complexes
- Deciphering the heterogeneity of breast cancer at the epigenetic and genetic levels
- Developing drugs to block malaria transmission
- Developing new computational tools for CRISPR genomics to advance cancer research
- Developing novel antibody-based methods for regulating apoptotic cell death
- Discovering novel paradigms to cure viral and bacterial infections
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Do membrane forces govern assembly of the deadly apoptotic pore?
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- E3 ubiquitin ligases in neurodegeneration, autoinflammation and cancer
- Engineering improved CAR-T cell therapies
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- Genomic rearrangement detection with third generation sequencing technology
- How does DNA damage shape disease susceptibility over a lifetime?
- How does DNA hypermutation shape the development of solid tumours?
- How platelets prevent neonatal stroke
- Human lung protective immunity to tuberculosis
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of dysregulated Tom40 in neurodegeneration
- Investigating the role of mutant p53 in cancer
- Lupus: proteasome inhibitors and inflammation
- Machine learning methods for somatic genome rearrangement detection
- Malaria: going bananas for sex
- Measurements of malaria parasite and erythrocyte membrane interactions using cutting-edge microscopy
- Measuring susceptibility of cancer cells to BH3-mimetics
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Mutational signatures of structural variation
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Revealing the epigenetic origins of immune disease
- Reversing antimalarial resistance in human malaria parasites
- Structural and functional analysis of DNA repair complexes
- Targeting human infective coronaviruses using alpaca antibodies
- Towards targeting altered glial biology in high-grade brain cancers
- Uncovering the real impact of persistent malaria infections
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding how malaria parasites sabotage acquisition of immunity
- Understanding malaria infection dynamics
- Understanding the mechanism of type I cytokine receptor activation
- Unveiling the heterogeneity of small cell lung cancer
- Using alpaca antibodies to understand malaria invasion and transmission
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to cross the blood brain barrier for drug delivery
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Lung cancer

This year, more Australians will die from lung cancer than from any other cancer. Lung cancer causes more than one million deaths globally each year, including 9000 people in Australia.
Though cancer survival rates have improved overall, only 1 in 5 people diagnosed with lung cancer will still be alive 5 years after diagnosis. Our research into lung cancer is focused on developing new ways to detect and treat lung cancer through a better understanding of its biology.
Our lung cancer research
Our lung cancer researchers focuses on:
- Understanding how normal lung cells develop, to determine what goes wrong when lung cancer develops.
- Establishing new systems in which to study lung cancer biology and therapy.
- Developing new approaches to treating lung cancer.
What is lung cancer?
Lung cancer is the abnormal, uncontrolled growth of lung cells. This is caused by changes to their genetic material. Different types of lung cancers arise from different cell types within the lung. The process by which this occurs is poorly understood.
Most lung cancer types are classified by their microscopic appearance. These include:
- Small cell lung cancer
- Non-small cell lung cancer: squamous cell carcinoma, adenocarcinoma and large cell carcinoma.
Other types of cancer can also occur in the lung. Some of these are rare types of cancer that arise from lung tissue.
Of lung cancers in Australia:
- 10% are small cell lung cancers.
- 60% are non-small cell lung cancer.
- 30% are rare types of lung cancer or cannot be definitively classified.
Cancer cells from other organs can also spread (metastasise) to the lung.
Mesothelioma is a type of cancer that starts in the lining of the chest and spreads into the lungs. Exposure to asbestos is strongly linked to mesothelioma. For more information about mesothelioma, please visit Cancer Council Victoria.
The treatment and outlook for lung cancer depends on the type of cancer, and how far the cancer cells have spread. Lung cancers may be:
- Contained within one part of a lung.
- Spread to several sites across the lungs.
- Spread (metastasised) to other parts of the body.
Most cases of lung cancer in Australia are detected at later, harder-to-treat stages.
What causes lung cancer?
Lung cancer occurs because of genetic changes in lung cells. These occur more frequently in people exposed to DNA-damaging agents such as tobacco smoke.
People who have smoked are 10 times more likely to develop lung cancer than non-smokers. Lung cancer is often associated with smoking (tobacco), however 1 in 3 women and 1 in 10 men diagnosed with lung cancer have no history of smoking. People who have never smoked tend to develop adenocarcinoma.
Specific cancer-promoting genetic changes have been discovered in adenocarcinomas in non-smokers. Understanding the genes that drive lung cancer growth and spread is allowing new treatments to be designed that can be matched to the genetic changes found in a patient’s lung cancer cells.
Risk factors for developing lung cancer
- Exposure to tobacco smoke or other forms of smoke, including smog or traffic fumes.
- Exposure to radiation such as the radioactive gas radon, or chest radiation to treat another cancer.
- Exposure to other cancer-causing (‘carcinogenic’) substances.
- Gender: amongst non-smokers, females are at higher risk of developing non-small cell lung cancer.
- Age: lung cancer rates increase with age.
- Lung inflammation and scarring, from other lung diseases.
- Family history: close relatives of a non-smoker with lung cancer are more likely to get the same disease.
How is lung cancer treated?
Treatment for lung cancer depends on the type of lung cancer and how far the cancer cells have spread. Currently, most lung cancers are only discovered when they have spread beyond the lungs, which reduces the likelihood of treatment curing the disease.
Lung cancers that are small and confined to one section of a lung can often be successfully removed by surgery.
Lung cancers are often treated with:
- Chemotherapy and radiotherapy to kill rapidly growing cells
- Targeted therapies that match medicines to the proteins that are driving the cancer’s growth. For example, lung cancers with high levels of the EGFR protein can be successfully treated with medications that block EGFR function
Support for people with lung cancer
For more information about how lung cancer is treated and patient support, please visit Cancer Council Victoria or the Lung Foundation Australia.
WEHI researchers are not able to provide specific medical advice specific to individuals. If you have lung cancer and wish to find out more information about clinical trials, please visit the Australian Cancer Trials or the Australian New Zealand Clinical Trials Registry, or consult your medical specialist.
Researchers:
Super Content:
Institute researchers have discovered how to use a potent combination of molecules to stop the growth of lung cancer and begin to shrink the tumours in preclinical models.
Scientists at the Walter and Eliza Hall Institute in Melbourne have discovered the cells that are thought to give rise to lung squamous cell carcinoma.
Dr Kate Sutherland and Dr Sarah Best have revealed a unique molecular signature in the blood that could be used to detect aggressive lung cancers with a simple blood test.
Melbourne researchers have identified a 'biomarker' that could improve treatment options for lung cancer by better identifying patients that will respond to new anti-cancer drugs.